English

INTERIM REPORT JANUARY – SEPTEMBER 2006

Report this content

• Sales of goods during the period amounted to SEK 897.8 (669.1) million, an increase of 34 percent.

• Operating income amounted to SEK 259.2 (59.0) million.

• Net income after tax amounted to SEK 186.7 (46.8) million.

• Earnings per share for the period were SEK 1.88 (0.47).

• Net income after tax for the third quarter amounted to SEK 35.3 (23.2) million.

• Q-Med’s first product within the area of body contouring, MACROLANE, approved for sales in Europe.

• The transfer of marketing and sales of DUROLANE to Smith & Nephew was begun during the quarter.


Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46(0)70-974 90 25
Erika Kjellberg Eriksson, Vice President and CFO
Tel: +46 (0)70-974 90 20

Documents & Links